JP2025514489A - 脳におけるｂａｇ３およびタンパク質品質管理 - Google Patents

脳におけるｂａｇ３およびタンパク質品質管理 Download PDF

Info

Publication number
JP2025514489A
JP2025514489A JP2024564848A JP2024564848A JP2025514489A JP 2025514489 A JP2025514489 A JP 2025514489A JP 2024564848 A JP2024564848 A JP 2024564848A JP 2024564848 A JP2024564848 A JP 2024564848A JP 2025514489 A JP2025514489 A JP 2025514489A
Authority
JP
Japan
Prior art keywords
bag3
vector
brain
polynucleotide
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514489A5 (OSRAM
Inventor
アーサー エム． フェルドマン
ヴァレリー マイヤーズ
Original Assignee
テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション filed Critical テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション
Publication of JP2025514489A publication Critical patent/JP2025514489A/ja
Publication of JP2025514489A5 publication Critical patent/JP2025514489A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024564848A 2022-05-03 2023-05-02 脳におけるｂａｇ３およびタンパク質品質管理 Pending JP2025514489A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263337914P 2022-05-03 2022-05-03
US63/337,914 2022-05-03
PCT/US2023/020659 WO2023215266A1 (en) 2022-05-03 2023-05-02 Bag3 and protein quality control in the brain

Publications (2)

Publication Number Publication Date
JP2025514489A true JP2025514489A (ja) 2025-05-02
JP2025514489A5 JP2025514489A5 (OSRAM) 2026-05-14

Family

ID=88646932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564848A Pending JP2025514489A (ja) 2022-05-03 2023-05-02 脳におけるｂａｇ３およびタンパク質品質管理

Country Status (11)

Country Link
US (1) US20250289858A1 (OSRAM)
EP (1) EP4518882A4 (OSRAM)
JP (1) JP2025514489A (OSRAM)
KR (1) KR20250010008A (OSRAM)
CN (1) CN119255814A (OSRAM)
AU (1) AU2023265031A1 (OSRAM)
CA (1) CA3250880A1 (OSRAM)
CL (1) CL2024003318A1 (OSRAM)
IL (1) IL316559A (OSRAM)
MX (1) MX2024013495A (OSRAM)
WO (1) WO2023215266A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705326A1 (en) * 2023-05-02 2026-03-11 Research Institute at Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
CN120478386B (zh) * 2025-07-18 2025-10-17 南京大学 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
CA3228845A1 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
CN109937045A (zh) * 2016-08-11 2019-06-25 天普大学-联邦高等教育系统 局部缺血/再灌注损伤
CN113286588A (zh) * 2018-10-19 2021-08-20 阿克里普斯一有限公司 神经性疾病的治疗
US20220023350A1 (en) * 2018-11-04 2022-01-27 Figene, Llc Treatment of cerebral hypoxia including stroke, chronic traumatic encephalopathy, and traumatic brain injury
WO2020150377A1 (en) * 2019-01-15 2020-07-23 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
WO2023069744A1 (en) * 2021-10-22 2023-04-27 Temple University Of The Commonwealth System Of Higher Education Bag3 methods and uses for treatment of inflammation

Also Published As

Publication number Publication date
EP4518882A4 (en) 2026-04-22
MX2024013495A (es) 2025-02-10
WO2023215266A1 (en) 2023-11-09
EP4518882A1 (en) 2025-03-12
CN119255814A (zh) 2025-01-03
CL2024003318A1 (es) 2025-03-21
AU2023265031A1 (en) 2024-11-28
US20250289858A1 (en) 2025-09-18
IL316559A (en) 2024-12-01
KR20250010008A (ko) 2025-01-20
CA3250880A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
EP3146982B1 (en) Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
CA3061368A1 (en) Compositions and methods of treating huntington's disease
JP7759174B2 (ja) 繊毛病のための遺伝子治療
WO2023061499A1 (en) Recombinant adeno-associated viral vectors for treating spinal muscular atrophy
EP4518882A1 (en) Bag3 and protein quality control in the brain
JP7811415B2 (ja) ビエッティ結晶性ジストロフィー治療のための遺伝子組換アデノ随伴ウイルスベクター
IL303308A (en) Products and methods for inhibiting the expression of myelin protein kp-22
TW202136515A (zh) 用於治療韓特氏病之腺相關病毒載體
US20250345464A1 (en) Gene therapy for treating neurodegenerative diseases
EP4286521A1 (en) Gene therapy for treating neurodegenerative diseases
JP2022525848A5 (OSRAM)
CN112955169A (zh) 用于肌萎缩性侧索硬化疗法中的胆固醇24-水解酶的表达载体
CA3179874A1 (en) Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders
JP2023526449A (ja) パーキンソン病を治療するための、増加した活性を有するパーキン変異体の遺伝子治療送達
CN119522285A (zh) 编码glp-2受体激动剂融合物的病毒载体及其在治疗短肠综合征中的用途
US20260091134A1 (en) Recombinant aav vectors for treating proteinopathies in central nervous system
EA051405B1 (ru) Векторы на основе аденассоциированного вируса для лечения болезни хантера
JP2025508988A (ja) 副甲状腺ホルモン融合物をコードするウイルスベクター及び副甲状腺機能低下症の治療におけるその使用
EP4486900A2 (en) Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
HK40052708A (zh) 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501